WO2023134787A3 - 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 - Google Patents

抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 Download PDF

Info

Publication number
WO2023134787A3
WO2023134787A3 PCT/CN2023/081308 CN2023081308W WO2023134787A3 WO 2023134787 A3 WO2023134787 A3 WO 2023134787A3 CN 2023081308 W CN2023081308 W CN 2023081308W WO 2023134787 A3 WO2023134787 A3 WO 2023134787A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
hepatocellular carcinoma
combination
treatment
Prior art date
Application number
PCT/CN2023/081308
Other languages
English (en)
French (fr)
Other versions
WO2023134787A2 (zh
Inventor
姚盛
冯辉
Original Assignee
上海君实生物医药科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海君实生物医药科技股份有限公司 filed Critical 上海君实生物医药科技股份有限公司
Publication of WO2023134787A2 publication Critical patent/WO2023134787A2/zh
Publication of WO2023134787A3 publication Critical patent/WO2023134787A3/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了抗PD-1抗体或其抗原结合片段与抗VEGF抗体或其抗原结合片段的药物组合，以及其在制备治疗肝细胞癌的药物中的用途；其中，所述抗PD-1抗体或其抗原结合片段包含氨基酸序列如SEQ ID NO：1、SEQ ID NO：2和SEQ ID NO：3所示的LCDR1、LCDR2和LCDR3，和氨基酸序列如SEQ ID NO：4、SEQ ID NO：5和SEQ ID NO：6所示的HCDR1、HCDR2和HCDR3。
PCT/CN2023/081308 2022-01-14 2023-03-14 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 WO2023134787A2 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210042847.0 2022-01-14
CN202210042847 2022-01-14

Publications (2)

Publication Number Publication Date
WO2023134787A2 WO2023134787A2 (zh) 2023-07-20
WO2023134787A3 true WO2023134787A3 (zh) 2023-09-07

Family

ID=87280138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/081308 WO2023134787A2 (zh) 2022-01-14 2023-03-14 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途

Country Status (1)

Country Link
WO (1) WO2023134787A2 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170166641A1 (en) * 2014-02-04 2017-06-15 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
CN108348575A (zh) * 2015-09-01 2018-07-31 日东制药株式会社 用于预防和治疗癌症或血管生成相关疾病的药物组合物，其含有作为有效成分的融合蛋白，该融合蛋白融合了肿瘤穿透肽和抗血管生成剂
CN110882385A (zh) * 2018-09-07 2020-03-17 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
WO2021228069A1 (zh) * 2020-05-12 2021-11-18 信达生物制药(苏州)有限公司 抗vegf抗体和抗pd-1抗体组合用于预防或治疗疾病的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170166641A1 (en) * 2014-02-04 2017-06-15 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
CN108348575A (zh) * 2015-09-01 2018-07-31 日东制药株式会社 用于预防和治疗癌症或血管生成相关疾病的药物组合物，其含有作为有效成分的融合蛋白，该融合蛋白融合了肿瘤穿透肽和抗血管生成剂
CN110882385A (zh) * 2018-09-07 2020-03-17 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
WO2021228069A1 (zh) * 2020-05-12 2021-11-18 信达生物制药(苏州)有限公司 抗vegf抗体和抗pd-1抗体组合用于预防或治疗疾病的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUDO MASATOSHI: "Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma", CANCERS, vol. 12, no. 5, 1 January 2020 (2020-01-01), pages 1089, XP093081142, DOI: 10.3390/cancers12051089 *

Also Published As

Publication number Publication date
WO2023134787A2 (zh) 2023-07-20

Similar Documents

Publication Publication Date Title
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
RS53157B (en) SCLEROSTINE ANTIBODIES
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
NZ608660A (en) Anti-cd48 antibodies and uses thereof
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
NZ714313A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ628943A (en) Human antibodies to clostridium difficile toxins
NZ600512A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
NZ590863A (en) Anti-hepcidin-25 selective antibodies and uses thereof
NZ592436A (en) Treatment with anti-alpha2 integrin antibodies
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
JP2013542194A5 (zh)
RU2014108047A (ru) Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
NZ598063A (en) Gram-positive bacteria specific binding compounds
JP2015503909A5 (zh)
NZ610153A (en) Novel anti-dr5 antibody
JP2023055904A5 (zh)
JP2024024114A5 (zh)
AR123480A1 (es) Moléculas de unión terapéuticas
ZA202211457B (en) Anti-cd73 antibody and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23740127

Country of ref document: EP

Kind code of ref document: A2